RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/JLP.JLP_140_17
Earlier and higher rates of cytomegalovirus infection in pediatric liver transplant recipients as compared to adults: An observational study
Financial support and sponsorship Financial support for the study was provided by Indian Council of Medical Research. Grant number VIR/38/2011/ECD-1.![](https://www.thieme-connect.de/media/10.1055-s-00044881/201802/lookinside/thumbnails/10-4103-jlp-jlp_140_17_221-1.jpg)
ABSTRACT
AIM: To study and compare the incidence and time of occurrence of cytomegalovirus (CMV) infection in the posttransplant period in adult and pediatric liver transplant recipients.
MATERIALS AND METHODS: Consecutive live donor liver transplant recipients not on CMV prophylaxis, were prospectively enrolled from March 2012 to September 2015 and followed up for 1 year post transplant to look for CMV infection. For analysis, patients were divided into pediatric (up to 18 years) and adult (>18 years) age groups.
RESULTS: The study population of 146 patients consisted of 132 adult and 14 pediatric patients. Overall CMV infection posttransplant was seen in 54/146 (36.98%) patients, and 16/54 (29.6%) patients developed CMV disease. Post-transplant CMV infection rate was significantly higher in pediatric patients(10/14 [71.4%]) as compared to adults (44/132 [33.4%]) (P = 0.004). Among adults, CMV infection was seen in 22 (50%) patients in the 1st month, 13 (29.5%) patients in the 2nd month, 5 (11.4%) patients in the 3rd month, 2 (4.5%) patients in the 4th month, and 1 (2.3%) patient each in the 5th and 6th month. However, in pediatric patients, all the patients having CMV infection had it in the 1st-month posttransplant (P = 0.003). The median time of occurrence of CMV infection was 11.5 (7.75–19.00) days in pediatric patients versus 30 (18.5–54.5) days in adult patients (P = 0.001).
CONCLUSIONS: The results of this study show a clear difference in the incidence and timeline of posttransplant CMV infection in pediatric patients as compared to adults.
Publikationsverlauf
Eingereicht: 02. September 2017
Angenommen: 18. Dezember 2017
Artikel online veröffentlicht:
19. Februar 2020
© 2018.
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 1973;49:103-6.
- 2 Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr 2002;20:348-51.
- 3 Razonable RR. Cytomegalovirus infection after liver transplantation: Current concepts and challenges. World J Gastroenterol 2008;14:4849-60.
- 4 Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013;85:893-8.
- 5 Weigand K, Schnitzler P, Schmidt J, Chahoud F, Gotthardt D, Schemmer P, et al. Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis. Transplant Proc 2010;42:2634-41.
- 6 Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: Updates on clinical management. World J Gastroenterol 2014;20:10658-67.
- 7 Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96:333-60.
- 8 Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol 2010;2:325-36.
- 9 Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007;13:1703-9.
- 10 Halasa N, Green M. Immunizations and infectious diseases in pediatric liver transplantation. Liver Transpl 2008;14:1389-99.
- 11 Green M, Michaels MG. Infections in pediatric solid organ transplant recipients. J Pediatric Infect Dis Soc 2012;1:144-51.
- 12 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
- 13 Bruminhent J, Razonable RR. Management of cytomegalovirus infection and disease in liver transplant recipients. World J Hepatol 2014;6:370-83.
- 14 Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001;3 Suppl 2:1-5.
- 15 Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
- 16 Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, et al. Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo) 2015;70:515-23.
- 17 Breinig MK, Zitelli B, Starzl TE, Ho M. Epstein-barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987;156:273-9.
- 18 Verma A, Palaniswamy K, Cremonini G, Heaton N, Dhawan A. Late cytomegalovirus infection in children: High incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients. Pediatr Transplant 2017;21:e12879. Available from: https://doi.org/10.1111/petr.12879. [Last accessed on 2017 Nov 11].
- 19 Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95.